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The identification and characterization of cancer stem cells might lead to more effective treat-
ments for some cancers by focusing therapy on the most malignant cells. To achieve this goal it 
will be necessary to determine which cancers follow a cancer stem cell model and which do not, to 
address technical issues related to tumorigenesis assays, and to test the extent to which cancer 
cell heterogeneity arises from genetic versus epigenetic differences.What Is the Cancer Stem Cell 
Model?
To devise more effective cancer ther-
apies it will be critical to determine 
which cancer cells have the potential 
to contribute to disease progression. If 
most cancer cells can proliferate exten-
sively and metastasize, then virtually 
all cells must be eliminated to cure the 
disease. Consistent with this view, tra-
ditional cancer therapies have sought 
to eliminate as many cancer cells as 
possible. In contrast to this approach, 
the cancer stem cell model proposes 
that the growth and progression of 
many cancers are driven by small sub-
populations of cancer stem cells (Reya 
et al., 2001; Dick, 2008). The cancer 
stem cell model does not address the 
question of whether cancers arise from 
normal stem cells. Rather, it suggests 
that irrespective of the cell-of-origin, 
many cancers may be hierarchically 
organized in much the same manner 
as normal tissues. Just as normal stem 
cells differentiate into phenotypically 
diverse progeny with limited prolifera-
tive potential, it is argued that cancer 
stem cells also undergo epigenetic 
changes analogous to the differentia-
tion of normal cells, forming phenotyp-
ically diverse nontumorigenic cancer 
cells that compose the bulk of cells 
in a tumor. These epigenetic changes 
are proposed to be associated with an 
irreversible (or rarely reversible) loss 
of tumorigenic capacity such that the 
vast majority of cells in these cancers 822 Cell 138, September 4, 2009 ©2009 Elsehave little capacity to contribute to dis-
ease progression. To characterize and 
eliminate the malignant cells in cancers 
that follow this model, it is necessary 
to focus on the small subpopulations of 
tumorigenic cells.
Consistent with the cancer stem cell 
model, certain cancers (including some 
germ cell cancers and some leukemias) 
have been recognized for decades to 
include neoplastic cells that differenti-
ate into post-mitotic derivatives. Germ 
cell cancers give rise to highly differ-
entiated cells, such as those that make 
neural tissue (Illmensee and Mintz, 
1976). Some leukemias give rise to 
highly differentiated hematopoietic 
cells (Fearon et al., 1986; Barabe et 
al., 2007). These cancers are obviously 
hierarchically organized. The more 
controversial question raised by recent 
studies is whether many other cancers 
exhibit a similar hierarchical organiza-
tion, even when overt differentiation is 
not evident among the cancer cells.
Compelling data support the can-
cer stem cell model in various human 
cancers including malignant germ 
cell cancers (Kleinsmith and Pierce, 
1964; Illmensee and Mintz, 1976), leu-
kemias (Lapidot et al., 1994; Bonnet 
and Dick, 1997), breast cancers (Al-
Hajj et al., 2003), brain cancers (Singh 
et al., 2004), and colon cancers (Dal-
erba et al., 2007; O’Brien et al., 2007; 
Ricci-Vitiani et al., 2007). In each case, 
only small subpopulations of cells can 
transfer disease upon transplantation vier Inc.into immunocompromised NOD/SCID 
mice, and markers have been identified 
that distinguish the leukemogenic/tum-
origenic cancer cells from the bulk pop-
ulations of nonleukemogenic/tumori-
genic cells. The ability to predict which 
cells are tumorigenic based on marker 
expression indicates that the tumori-
genic cells are intrinsically different 
from nontumorigenic cancer cells. Yet, 
no clear morphological distinction was 
found between tumorigenic and nontu-
morigenic breast cancer cells (Al-Hajj 
et al., 2003), implying that differentia-
tion need not be overt for the cells to be 
hierarchically organized. The observa-
tion that tumorigenic cells have tended 
to be rare in the cancers found so far to 
follow a cancer stem cell model implies 
that epigenetic differences distinguish 
tumorigenic from nontumorigenic cells 
because it is implausible that only rare 
cancer cells have a genotype permis-
sive for extensive proliferation. Tum-
origenic cancer stem cells also form 
phenotypically diverse nontumorigenic 
cells, recapitulating at least some of 
the heterogeneity in the tumors from 
which they derive.
Despite strong data supporting the 
stem cell model in some cancers, it is 
important to acknowledge a number of 
caveats. There is no direct evidence in 
these cancers that tumorigenic cells 
differ from nontumorigenic cells as a 
result of epigenetic rather than genetic 
differences. Moreover, the conclusion 
that transplanted cancer stem cells 
Table 1. Models to Explain Cancer Cell Heterogeneity
Cancer Stem Cell Model (Stochastic) Clonal Evolution Modela 
Frequency of cancer cells with tumorigenic potential Rare to moderate High
Phenotype of cancer cells Heterogeneous Heterogeneous or homogeneous
Tumor organization Hierarchical Not necessarily hierarchical
Intrinsic differences between tumorigenic and 
 nontumorigenic cells
Stable, epigenetic Unstable, epigenetic or genetic
Rational approach to therapy Possible to target only tumorigenic cells Target most or all cells
Compelling clinical evidence Germ lineage cancers High-grade B cell lymphoblastic leukemiab
aThe clonal evolution model holds that genetic and epigenetic changes occur over time in individual cancer cells, and that if such changes confer a 
selective advantage they will allow individual clones of cancer cells to out-compete other clones. Clonal evolution can lead to genetic heterogeneity, 
conferring phenotypic and functional differences among the cancer cells within a single patient. Note that the clonal evolution and cancer stem cell 
models are not mutually exclusive in cancers that follow a stem cell model, as cancer stem cells would be expected to evolve by clonal evolution. 
However, heterogeneity in cancers that do not follow a cancer stem cell model (not hierarchically organized into epigenetically distinct tumorigenic 
and nontumorigenic populations) could be determined entirely by clonal evolution.
bB cell lymphoblastic leukemias have extraordinarily high frequencies of leukemogenic cells that are not hierarchically organized in a mouse model 
(Williams et al., 2007) and appear homogeneous by histopathology in patients, yet heterogeneity can arise in sensitivity to therapy through clonal 
genetic changes.can recapitulate the heterogeneity of 
the tumors from which they derive is 
based on limited analyses of only two 
or three surface markers. It has not yet 
been determined whether there is also 
genetic heterogeneity within the pri-
mary tumors that is not recapitulated 
after cancer stem cell transplantation. 
It therefore remains possible that the 
functional and phenotypic diversity 
within these cancers is underestimated 
and partially genetically determined.
The cancer stem cell model has been 
carefully tested in only a small subset of 
cancers. Although this model is often 
assumed to apply widely to other can-
cers, recent data demonstrate that leu-
kemogenic/tumorigenic potential is a 
common attribute of cells in some can-
cers (Kelly et al., 2007; Williams et al., 
2007; Quintana et al., 2008) making this 
a questionable assumption. Second, 
the NOD/SCID mouse transplantation 
assay, which has been the source of 
most of the compelling data supporting 
the cancer stem cell model, dramati-
cally underestimates the frequency of 
human cancer cells with tumorigenic 
potential in some cancers (Quintana 
et al., 2008). This suggests the need to 
re-evaluate some of the evidence sup-
porting the model using assays that are 
more permissive for the engraftment of 
human cancer cells. If some cancers 
that are currently thought to follow a 
cancer stem cell model actually have 
common tumorigenic cells and hetero-
geneity is generated through genetic 
and epigenetic mechanisms, the pro-gression of these cancers may be more 
accurately described by the clonal evo-
lution model (Nowell, 1976) (Table 1).
The Cancer Stem Cell Model and 
Clinical Behavior
The response of some cancers to ther-
apy does appear to be influenced by 
epigenetic differences between leu-
kemogenic/tumorigenic cells and their 
nonleukemogenic/tumorigenic progeny. 
For example, chronic myeloid leukemia 
appears to be sustained by leukemic 
stem cells that are more resistant to the 
drug imatinib than their differentiated 
progeny (O’Hare et al., 2006; Oravecz-
Wilson et al., 2009). There is also evi-
dence that cancer stem cells in gliomas 
(Bao et al., 2006) and breast cancers 
(Li et al., 2008; Diehn et al., 2009) might 
be intrinsically more resistant to ther-
apy than other cells in these cancers. 
Conversely, the undifferentiated cells 
that drive testicular cancer progression 
are more sensitive to cisplatin therapy 
than the differentiated cells they form 
(Masters and Koberle, 2003). This indi-
cates that although the epigenetic state 
of cancer stem cells can influence the 
response to therapy, these cells are not 
always more resistant than their nontu-
morigenic progeny.
Although the cancer stem cell model 
is likely to explain the clinical behavior 
of some cancers, the observation that 
many cancers re-emerge after treat-
ment does not necessarily imply that 
the cells that survive therapy are intrin-
sically more resistant than the cells Cell 138, Sthat are killed. All cancer cells within a 
given patient might have a similar prob-
ability of surviving and expanding after 
therapy, or the surviving cells might be 
in a protective microenvironment. In 
cases where there are intrinsic differ-
ences in the sensitivity of cancer cells 
to therapy, these differences can be 
genetically determined (Sikic, 2008). 
Therefore, therapy-resistant cancer 
stem cells do not necessarily exist in 
many cancers. Resistance to therapy 
in many cancers may be explained 
by epigenetic and genetic differences 
among tumorigenic cancer cells that 
lack hierarchical organization, just as 
predicted by clonal evolution (Nowell, 
1976).
Epigenetic differences between can-
cer stem cells and their progeny are 
likely to be an important determinant of 
the clinical behavior of some cancers 
but not others, whereas clonal evolution 
is likely to be important in all cancers. 
The cancer stem cell model and the 
clonal evolution model are not mutu-
ally exclusive in cancers that are hier-
archically organized into epigenetically 
distinct populations of tumorigenic and 
nontumorigenic cancer cells. In these 
cancers, clonal evolution still occurs 
in the cancer stem cells (Barabe et al., 
2007). For example, the leukemic stem 
cells that maintain chronic myeloid leu-
kemia despite imatinib therapy would 
be selected to develop imatinib resis-
tance mutations over time by clonal 
evolution (Shah et al., 2007). How-
ever, in cancers in which tumorigenic eptember 4, 2009 ©2009 Elsevier Inc. 823
Figure 1. Testing the Cancer Stem Cell Model
During the dissociation of solid tumors (left), conditions must be optimized to maximize the preservation of cell viability and surface marker expression. During 
cell separation (middle), care must be taken to use viability dyes and markers to exclude dead cells, hematopoietic cells, endothelial cells, and stromal cells (if 
possible) by flow cytometry from the cancer cell preparation. The tumorigenicity of all cells must be tested in assays optimized for the engraftment of human 
cancer cells (right). For nontumorigenic cell populations, it is critical to confirm that they contain live cancer cells, rather than normal cells or debris. If markers 
can be identified that distinguish tumorigenic from nontumorigenic cells, an important question is whether these cancer cell populations are distinguished by 
epigenetic rather than genetic differences.potential is common and there is little 
evidence of hierarchical organization, 
heterogeneity in response to therapy 
likely arises primarily from clonal evo-
lution, not from epigenetic differences 
between cancer stem cells and their 
progeny.
The Cancer Stem Cell Model 
Addresses Potential, Not Fate
The cancer stem cell literature has 
addressed the potential of cancer cells 
to contribute to disease, not the actual 
fate of cells within patients. Potential 
describes what cells are capable of doing 
under permissive conditions, whereas 
fate describes what they actually do in 
a specific circumstance. The central 
tenet of the cancer stem cell literature 
has been that the vast majority of cells 
within at least some cancers have lost 
the potential to proliferate extensively, as 
revealed by their inability to transfer dis-
ease to immunocompromised mice and 
in some cases by their inability to pro-
liferate in culture. It has been proposed 
that the nontumorigenic cancer cells can 
be ignored in therapy because they lack 
the potential to contribute to disease.
These inferences regarding tumori-
genic potential are sometimes confused 
with the question of which cells are actu-
ally fated to contribute to disease in 
patients. The issue of fate is a different 
question that has not been addressed by 
the cancer stem cell field. Indeed, there 824 Cell 138, September 4, 2009 ©2009 Elsare almost no data in all of cancer biol-
ogy that address the question of whether 
many cancer cells or few cancer cells are 
actually fated to contribute to disease in 
patients because this question can only 
be addressed within the patient and 
therefore is experimentally less feasible. 
It is important to bear in mind that just 
because a cell has the potential to form 
a tumor does not mean that it actually 
does so within a patient. Cancer cells 
with tumorigenic potential might be held 
in check, transiently or permanently, by 
environmental or immunological mecha-
nisms that prevent them from actually 
contributing to disease.
To test the cancer stem cell model, it is 
necessary to identify all of the cells with 
the potential to proliferate extensively 
and to contribute to disease (Figure 1). 
If a cancer cell has the potential to form 
a tumor in any assay, then it has not 
entered an epigenetic state in which it 
has lost the ability to proliferate, and it is 
perilous to ignore this cell when treating 
a patient. For this reason, tumorigenic 
potential is presumably the key consid-
eration when devising therapeutic strat-
egies because therapies must target all 
cells with the potential to contribute to 
disease in a patient. It is not safe to base 
therapeutic strategies on assumptions 
regarding fate because fate is context 
dependent. Cancer cells fated to con-
tribute to disease in one context (such as 
in a primary tumor) may be quite different evier Inc.from cells fated to contribute to disease 
in other contexts (such as after metasta-
sis or therapy). Rational approaches to 
therapy must therefore target all of the 
cells with the potential to contribute to 
disease.
A fundamental question is whether 
immunocompromised mice are reliable 
models for studying human cancer. The 
answer may depend upon the aspect 
of cancer biology being studied. Trans-
plantation into highly immunocompro-
mised mice is the best, albeit imperfect, 
way of assessing which human cancer 
cells have the potential to form tumors/
leukemias. In contrast, such stud-
ies often cannot address the extent to 
which these cells might be positively or 
negatively regulated by environmental 
mechanisms, such as immune function, 
in patient tissues. For example, an inter-
esting question is whether some cancer 
cells are more immunogenic than oth-
ers in patients. This question should not 
be confused with the cancer stem cell 
model, which addresses the very differ-
ent issue of whether intrinsic epigenetic 
differences among cancer cells limit 
their proliferative potential. The question 
of whether some cancer cells are more 
immunogenic than others in patients 
may not be directly testable because it 
requires tumorigenesis assays that rep-
licate the syngeneic immune response 
that occurs in patients against their 
own tumors. The xenogeneic immune 
response that occurs in mice against 
human cells is much more powerful 
and depends upon very different immu-
nological mechanisms than the syn-
geneic response in patients does. For 
these reasons, it is critical to distinguish 
between questions of potential that can 
be addressed in xenograft models and 
questions of fate that must be addressed 




The xenogeneic immune response that 
mice mount against human cells is a 
critical variable that determines the 
ability of human cancer cells to engraft 
in mice. Even highly immunocompro-
mised NOD/SCID mice, lacking B and 
T cells, retain natural killer cells that 
reject most transplanted human cells 
(McKenzie et al., 2005). As human can-
cer cells are transplanted into increas-
ingly immunocompromised mice, fewer 
and fewer cells are required to transfer 
disease (Bonnet and Dick, 1997; Feur-
ing-Buske et al., 2003; Kennedy et al., 
2007; Quintana et al., 2008).
The use of NOD/SCID mice can 
underestimate the frequency of human 
cancer cells with tumorigenic poten-
tial due to the xenogeneic immune 
response in these mice. The percent-
age of melanoma cells that form tumors 
in NOD/SCID mice deficient in the 
interleukin-2 receptor γ chain (IL2Rγnull 
mice), which lack T, B, and natural killer 
cells, is orders of magnitude higher 
than the percentage that form tumors 
in NOD/SCID mice. Although only ~1 in 
a million melanoma cells form tumors 
in NOD/SCID mice, 1 in 4 can form 
tumors in NOD/SCID IL2Rγnull mice 
when coinjected with Matrigel (Quin-
tana et al., 2008). Thus tumorigenic 
potential is a common attribute of cells 
in some human cancers, even though 
tumorigenic cells can appear to be rare 
in the NOD/SCID mouse transplanta-
tion assay.
Although this suggests that the fre-
quency of leukemogenic/tumorigenic 
cells in other cancers should be re-
evaluated in optimized assays, it does 
not necessarily mean that such cells 
will be as common in other cancers 
as they are in melanoma. Additional Figure 2. Cancers Need Not Be Hierarchically Organized to Be Heterogeneous
CD133 expression distinguishes tumorigenic from nontumorigenic cancer cells in some brain tumors 
and some colon cancers (Singh et al., 2004; O’Brien et al., 2007; Ricci-Vitiani et al., 2007). However, the 
expression of CD133 (or other stem cell markers) by small subpopulations of cells in other cancers does 
not necessarily mean that these cells are cancer stem cells. CD133 expression was heterogeneous in 
melanomas from 6 of 12 patients (Quintana et al., 2008). 
(A) Representative CD133 staining in one of these melanomas (positive staining was defined using an 
isotype control). 
(B) A reanalysis of the CD133− (blue) and CD133+ (red) fractions after separation using magnetic beads. 
(C) When these cells were transplanted into NOD/SCID IL2Rγnull mice, both the CD133− and CD133+ frac-
tions of cells contained high frequencies of tumorigenic cells (D) (Quintana et al., 2008). The tumors that 
arose from CD133− cells and from CD133+ cells contained similar proportions of CD133− and CD133+ 
cells. This indicates that individual cancer cells can recapitulate the heterogeneity of the tumors from 
which they derive, even when there is no evidence that the cancer follows a cancer stem cell model or 
that tumorigenic cells are hierarchically organized.work is required to determine which 
cancers have common leukemogenic/
tumorigenic cells and which have rare 
leukemogenic/tumorigenic cells (Fig-
ure 1). This is a critical issue as models 
and therapies must account for the full 
spectrum of human cancer cells with 
the potential to contribute to disease.
Even highly immunocompromised 
NOD/SCID IL2Rγnull mice may underes-
timate the frequency of human cancer Cell 138, Scells with tumorigenic potential due to 
differences between the mouse and 
human tissue environments. Incompat-
ibilities between mouse ligands and 
human receptors for certain growth 
factors and adhesion molecules may 
impair the survival, proliferation, or 
migration of human cells in mice. More-
over, human cancers are often hetero-
topically transplanted into mice (that is, 
transplanted into locations that differ eptember 4, 2009 ©2009 Elsevier Inc. 825
from the locations in which the tumors 
normally arise in patients). Differences 
between the native environment of can-
cer cells in patients and the environment 
into which these cells are transplanted 
in mice can reduce the engraftment of 
cells with tumorigenic potential. These 
effects can be mitigated by expressing 
human growth factors in mice (Lapi-
dot et al., 1994; Feuring-Buske et al., 
2003) and by optimizing the site of 
transplantation (Kennedy et al., 2007). 
As tumorigenesis assays are optimized 
(Table S1 available online), it is likely 
that estimates of the frequency of cells 
with leukemogenic/tumorigenic poten-
tial will increase significantly in most 
human cancers.
The Biological Basis of Cancer Cell 
Heterogeneity
The cancer stem cell model posits 
that differences in tumorigenic poten-
tial among cancer cells from the same 
patient are largely epigenetically deter-
mined. Moreover, this model requires 
such epigenetic differences to be 
largely irreversible because if nontu-
morigenic cells could efficiently revert 
to the tumorigenic state it would not 
be possible to distinguish tumorigenic 
from nontumorigenic cells and such 
cancers would not be hierarchically 
organized. Consistent with the model, 
cancer stem cells differentiate into 
nontumorigenic cancer cells in germ 
lineage cancers (Kleinsmith and Pierce, 
1964; Illmensee and Mintz, 1976), 
chronic myeloid leukemia (O’Hare et 
al., 2006), and some brain tumors (Pic-
cirillo et al., 2006).
The extent to which cancer cells dif-
ferentiate to a nontumorigenic state 
has not been directly tested in most 
other cancers. The ability to distinguish 
rare tumorigenic cells from nontumori-
genic cells in several cancers based 
on marker expression implies that the 
tumorigenic cells are epigenetically 
distinct from nontumorigenic cells 
in these cancers (e.g., Lapidot et al., 
1994; Bonnet and Dick, 1997; Al-Hajj 
et al., 2003; Singh et al., 2004; O’Brien 
et al., 2007; Ricci-Vitiani et al., 2007). 
However, if tumorigenic cells are much 
more common in some of these can-
cers than currently estimated, a legiti-
mate question arises about whether 826 Cell 138, September 4, 2009 ©2009 Elsethey are really distinguished from non-
tumorigenic cells by epigenetic mech-
anisms. Some cancer cells would be 
expected to lack tumorigenic potential 
because they are fated to undergo cell 
death or senescence due to deleteri-
ous genetic changes or localization to 
unsupportive environments. If nontum-
origenic cells represent 50% or 75% of 
cells in a tumor, it is conceivable that 
their lack of tumorigenic potential is 
explained entirely by genetic and envi-
ronmental mechanisms. Therefore, 
in cancers in which tumorigenic cells 
are common, it will be vital to assess 
whether epigenetic differences distin-
guish tumorigenic and nontumorigenic 
cells to determine whether such can-
cers follow a cancer stem cell model. 
The mere observation that some can-
cer cells are more tumorigenic than 
others is entirely consistent with clonal 
evolution (Table 1).
Melanoma illustrates these issues. 
We estimate that at least 25% of human 
melanoma cells have tumorigenic poten-
tial, and we have not been able to iden-
tify any markers that distinguish tumori-
genic from nontumorigenic melanoma 
cells, despite considerable effort (Quin-
tana et al., 2008). This does not prove 
that melanoma does not follow a cancer 
stem cell model as markers that distin-
guish tumorigenic from nontumorigenic 
cells could be identified in the future. 
Nevertheless, the simplest interpreta-
tion of the currently available data is 
that many melanoma cells have a simi-
lar tumorigenic capacity, that these cells 
are not hierarchically organized (Figure 
2), and that melanoma does not, there-
fore, appear to follow a cancer stem cell 
model. If markers are identified in future 
that can distinguish tumorigenic from 
nontumorigenic melanoma cells, it will 
be important to test whether these cells 
are distinguished by genetic differences, 
epigenetic differences, or localization to 
distinct environments.
Distinguishing Tumorigenic from 
Nontumorigenic Cells
Evidence that tumorigenic cells can 
be distinguished from nontumorigenic 
cells based on marker expression is 
a cornerstone of the cancer stem cell 
model. Without this evidence, it would 
be possible that all cancer cells have vier Inc.the same stochastic probability of pro-
liferating or forming a tumor. Thus, the 
ability of markers to distinguish leuke-
mogenic/tumorigenic cells from non-
leukemogenic/nontumorigenic cells in 
leukemias (Lapidot et al., 1994; Bonnet 
and Dick, 1997), breast cancers (Al-Hajj 
et al., 2003), brain cancers (Singh et 
al., 2004), and colon cancers (Dalerba 
et al., 2007; O’Brien et al., 2007; Ricci-
Vitiani et al., 2007) is strong evidence 
that these cancers follow a cancer stem 
cell model.
As markers are further evaluated in 
additional studies and in larger num-
bers of tumors, some markers will 
likely prove less robust than they cur-
rently appear. CD133 appeared to be a 
robust marker of brain tumor stem cells 
in initial studies (Singh et al., 2004; Bao 
et al., 2006), but more recent studies 
have found that this marker does not 
distinguish tumorigenic from nontu-
morigenic cells in many other brain 
tumors (Joo et al., 2008; Ogden et al., 
2008; Wang et al., 2008). This raises 
the possibility that some brain tumors 
may follow a cancer stem cell model, 
whereas others do not. This is likely to 
be a general issue in a variety of can-
cers as many of the markers used to 
distinguish tumorigenic from nontum-
origenic cancer cells may turn out to 
work in some circumstances but not 
in others. It is important to remember 
that in the absence of markers that 
can distinguish tumorigenic from non-
tumorigenic cancer cells, there is no 
evidence that a cancer follows a can-
cer stem cell model as there can be 
no evidence of intrinsic differences 
among cancer cells in tumorigenicity 
(without markers there is no way to rule 
out the possibility that all cancer cells 
have a similar stochastic probability of 
forming tumors). It will be important to 
determine what fraction of patients with 
each type of cancer actually have can-
cers that express informative markers 
and follow a cancer stem cell model. 
Given these uncertainties in marker 
robustness, markers alone should not 
be relied upon to assess potential bio-
logical differences between tumori-
genic and nontumorigenic cells; func-
tional assays are required to confirm 
differences in therapy sensitivity and 
other biological properties.
There are also a number of technical 
pitfalls that can falsely appear to dis-
tinguish tumorigenic from nontumori-
genic cancer cells (Table S1). Tumors 
contain neoplastic cancer cells as well 
as non-neoplastic stromal and immune 
cells, but markers are rarely available 
to distinguish them. Many solid cancer 
stem cell studies have not even taken 
advantage of known hematopoietic 
and endothelial markers to exclude 
these cells from sorted cancer cell 
preparations. Thus, it is possible that 
the depletion of tumorigenic activity 
in “nontumorigenic” cell populations 
in some studies could be caused by 
the presence of non-neoplastic cells 
in these populations rather than by the 
presence of nontumorigenic cancer 
cells. Additionally, debris from dying 
cells and necrotic tissue can appear 
indistinguishable from live cells by 
flow cytometry if the debris contains 
little DNA and does not take up viabil-
ity dyes. As a result, nontumorigenic 
fractions can be identified from some 
tumors, not because large numbers of 
cancer cells lack tumorigenic poten-
tial, but because the tumors yield 
large quantities of debris that is dif-
ficult to distinguish from live cells by 
flow cytometry. It is critical to exclude 
debris as much as possible from can-
cer cell preparations and to examine 
all sorted fractions by microscopy to 
ensure the presence of live cells.
Some Cancers Follow a Cancer 
Stem Cell Model, Others Do Not
Although studies of human cancers 
in immunocompromised mice can be 
confounded by species incompatibili-
ties, the conclusion that some cancers 
follow a cancer stem cell model has 
been confirmed in studies of mouse 
cancers. Even when cells from some 
mouse leukemias (Deshpande et al., 
2006; Krivtsov et al., 2006; Yilmaz et 
al., 2006), mouse breast cancers (Cho 
et al., 2008; Vaillant et al., 2008; Zhang 
et al., 2008), and mouse squamous cell 
carcinomas (Malanchi et al., 2008) are 
transplanted into fully histocompatible 
wild-type recipient mice, some of these 
cancers appear to follow a cancer stem 
cell model marked by the presence of 
small subpopulations of cancer cells 
that have much more leukemogenic/tumorigenic capacity than the bulk 
population of neoplastic cells. As a 
result of parallel studies of human and 
mouse cancers, there is strong evi-
dence that some cancers follow a stem 
cell model.
Some cancers follow a stem cell 
model, but it is dangerous to gen-
eralize. The cancer stem cell model 
appears to apply to some mouse acute 
myeloid leukemias (Deshpande et al., 
2006; Krivtsov et al., 2006; Yilmaz et 
al., 2006) but not others (Kelly et al., 
2007). It would not be surprising if can-
cers with different constellations of 
mutations differ in the extent to which 
they follow a stem cell model. The same 
point applies to markers. Just because 
CD133 expression identifies cancer 
stem cells in some cancers does not 
mean this marker will be informative in 
other cancers (Figure 2). Markers should 
be validated in significant numbers of 
patients before they are assumed to be 
informative in all patients. It is neces-
sary to rigorously test the cancer stem 
cell model in every circumstance in 
which it is hypothesized to apply, using 
assays that are optimized to detect the 
full spectrum of cells with tumorigenic 
potential.
The Significance of Cancer Cell 
Heterogeneity
Cancers that do not follow a cancer stem 
cell model are not necessarily homoge-
neous. Although we have not been able 
to identify any markers that distinguish 
tumorigenic from nontumorigenic mela-
noma cells, we observe considerable 
heterogeneity within individual mela-
nomas in terms of cellular morphology, 
pigmentation, and marker expression 
(Quintana et al., 2008). There are likely 
biologically and clinically important 
forms of heterogeneity among cancer 
cells that are unrelated to distinctions 
between tumorigenic and nontumori-
genic cells. The clonal evolution model 
predicts that there should be genetic 
heterogeneity among cancer cells that 
leads to heterogeneity in phenotype, 
function, and response to therapy. Epi-
genetic differences are presumably lay-
ered on top of these genetic differences 
to confer additional heterogeneity. Yet, 
the mere existence of such heterogene-
ity does not imply that cancers must be Cell 138, Shierarchically organized into tumorigenic 
and nontumorigenic fractions, nor does 
the lack of hierarchical organization 
imply that cancers are homogeneous 
(Figure 2).
Although the cancer stem cell model 
was introduced to describe cancers 
in which intrinsic epigenetic differ-
ences among cancer cells cause 
these cells to reside in a hierarchy of 
tumorigenic and nontumorigenic cells 
(Reya et al., 2001; Dick, 2008), the term 
cancer stem cell is now used so pro-
miscuously as to threaten any mean-
ing. Some have described the normal 
cell that is transformed into cancer 
(the cell-of-origin) as the cancer stem 
cell, even though the cancer stem cell 
model does not address the cell-of-ori-
gin (for more discussion of this issue, 
see Dick, 2008). Others have begun to 
describe any clonogenic cancer cell as 
a cancer stem cell. The cancer stem 
cell model becomes meaningless and 
can no longer be readily distinguished 
from the clonal evolution model when 
any clonogenic cancer cell is consid-
ered a cancer stem cell. Although it is 
true that cancer stem cells need not 
be rare (Kelly et al., 2007), cancers in 
which most cells are similarly tumori-
genic do not follow a cancer stem cell 
model because there can be no mean-
ingful hierarchy within these tumors. 
Indeed, in cases in which most cancer 
cells have tumorigenic potential there 
is little that can be gained in terms of 
therapy or biology by distinguishing 
these cells from minority populations 
of nontumorigenic cells. Some cancers 
are just good old fashioned cancer in 
which nearly every cell is bad.
Whether a cancer is comprised of 
common tumorigenic cells that are het-
erogeneous as a result of clonal evo-
lution or whether the cancer contains 
a hierarchy of epigenetically distinct 
tumorigenic and nontumorigenic cells, 
cancers often arise and progress due to 
dysregulation of self-renewal pathways 
borrowed from normal stem cells (Reya 
et al., 2001). Carcinogenic mutations can 
inappropriately activate normal stem cell 
self-renewal pathways. In some cases, 
carcinogenesis preserves the epigenetic 
programs that regulate stem cell differ-
entiation, allowing cancer stem cells to 
form a hierarchy of cancer cells. In other eptember 4, 2009 ©2009 Elsevier Inc. 827
cases, carcinogenesis arrests differen-
tiation, potentially allowing a plurality of 
cancer cells to maintain indefinite pro-
liferative potential, avoiding hierarchical 
organization. The question of whether a 
cancer follows a cancer stem cell model 
is likely to be determined by the cell-of-
origin, the carcinogenic mutations, and 
whether the mutations block the epige-
netic programs that underlie differentia-
tion. Studies of stem cell self-renewal 
mechanisms are likely to inform our 
understanding of cancer proliferation, 
even in cancers that are not hierarchi-
cally organized.
Conclusions
Cancers that contain a hierarchy of 
epigenetically distinct populations of 
tumorigenic and nontumorigenic cells 
might be more effectively studied and 
treated by focusing on the tumorigenic 
cells, particularly when those cells are 
rare. But this field will only achieve 
its promise if we carefully distinguish 
between cancers that follow a cancer 
stem cell model and those that do not. 
Therapies designed to eliminate only 
a small subpopulation of cancer cells 
will likely not have a clinical impact on 
cancers in which tumorigenic cells rep-
resent most of the cancer cells in the 
patient. Additional testing of the can-
cer stem cell model will be required in 
all cancers to determine what fraction 
of cases actually follow the model, and 
how often existing markers are infor-
mative. Such testing is likely to yield a 
complex picture involving differences 
between cancers, and even between 
patients with the same cancer, in terms 
of the frequency of tumorigenic cells, 
the degree of hierarchical organization, 
and the extent to which markers can 
distinguish tumorigenic from nontum-
origenic cells.
The use of xenotransplantation mod-
els will lead to a better understanding of 
tumorigenesis in vivo, the developmen-
tal relationship between cancer cells, 
and even new therapies. However, it is 
critical that such models be optimized 
for the engraftment of human cells if 
we are to draw conclusions regard-
ing the frequency of tumorigenic cells. 
The frequency of human cancer cells 
with leukemogenic/tumorigenic poten-
tial has likely been underestimated in 828 Cell 138, September 4, 2009 ©2009 ElseNOD/SCID xenotransplantation assays, 
in some cases modestly and in other 
cases drastically. In cancers in which 
leukemogenic/tumorigenic cells are 
common, it will be critical to test 
whether these cells are distinguished 
from nontumorigenic cells by epige-
netic or genetic differences. By opti-
mizing xenotransplantation assays we 
will gain a more complete understand-
ing of the spectrum of human cancer 
cells that have the potential to contrib-
ute significantly to disease. To capital-
ize on the promise of cancer stem cell 
biology, it is worthwhile to remain cog-
nizant of the limitations of the existing 
data and the need to improve the preci-
sion of markers and assays.
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